The Renewal of Cancer Immunotherapy

Affiliations

Editorial

Jenny Bulgarelli et al. Vaccines (Basel). 2023.

. 2023 Mar 4;11(3):592.

doi: 10.3390/vaccines11030592.

¹ Immunotherapy, Cell Therapy and Biobank Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.

Abstract

Cancer immunotherapy embraces many current, promising therapeutic approaches to eradicate tumors by activating host antitumor activity [...].

The authors declare no conflict of interest.

1. Wolfson B., Franks S., Hodge J. Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy. Vaccines. 2021;9:509. doi: 10.3390/vaccines9050509. - DOI - PMC - PubMed
1. Postow M.A., Chesney J., Pavlick A.C., Robert C., Grossmann K., McDermott D., Linette G.P., Meyer N., Giguere J.K., Agarwala S.S., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 2015;372:2006–2017. doi: 10.1056/NEJMoa1414428. - DOI - PMC - PubMed
1. Wolchok J.D., Chiarion-Sileni V., Gonzalez R., Rutkowski P., Grob J.J., Cowey C.L., Lao C.D., Wagstaff J., Schadendorf D., Ferrucci P.F., et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 2017;377:1345–1356. doi: 10.1056/NEJMoa1709684. - DOI - PMC - PubMed
1. Gomes-Silva D., Ramos C.A. Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line. Biotechnol. J. 2018;13:1700097. doi: 10.1002/biot.201700097. - DOI - PMC - PubMed
1. Avanzi M.P., Brentjens R.J. Emerging Role of CAR T Cells in Non-Hodgkin’s Lymphoma. J. Natl. Compr. Cancer Netw. 2017;15:1429–1437. doi: 10.6004/jnccn.2017.7045. - DOI - PubMed